Cyclophosphamide therapy for scleroderma

    loading  Checking for direct PDF access through Ovid

Abstract

Pulmonary manifestations are the most common cause of death in patients with scleroderma. Consequently, the importance of treatment of both interstital lung disease and pulmonary hypertension has become increasingly evident. Until a placebo-controlled study of any drug has shown its beneficial effect on pulmonary dysfunction, cyclophosphamide may be useful for the treatment of scleroderma lung disease.

Related Topics

    loading  Loading Related Articles